Statin-induced myopathies

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 859-866

  Tomaszewski, Michał ^a   Stȩpień, Karolina M ^b   Tomaszewska, Joanna ^a   Czuczwar, Stanisław J ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Myalgia; Myotoxicity; Rhabdomyolysis; Statins

Indexed keywords

ATORVASTATIN; CALCIUM; CERIVASTATIN; COLCHICINE; CREATINE KINASE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FUSIDIC ACID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SILDENAFIL; SIMVASTATIN; UBIQUINONE;

ACUTE KIDNEY FAILURE; APOPTOSIS; ATHEROSCLEROSIS; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENETIC PREDISPOSITION; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LOW DRUG DOSE; MEMBRANE DEPOLARIZATION; MONOTHERAPY; MORTALITY; MUSCLE CELL; MUSCLE MITOCHONDRION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NONHUMAN; PATHOPHYSIOLOGY; POLYPHARMACY; PRESCRIPTION; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT;

EID: 80053373582     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70601-6     Document Type: Review

References (51)

1. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol, 2007, 50, 409-418. (Pubitemid 47096680)
2. Baer AN, Wortmann RL: Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol, 2007, 19, 67-73. (Pubitemid 44885730)
3. Bell DS: Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J, 2010, 103, 690-692.
4. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther, 2005, 19, 403-414. (Pubitemid 43228152)
5. Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol, 2007, 99, 1409-1412. (Pubitemid 46686635)
6. Chang JT, Staffa JA, Parks M, Green L: Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf, 2004, 13, 417-426. (Pubitemid 38996852)
7. Christopher-Stine L: Statin myopathy: an update. Curr Opin Rheumatol, 2006, 18, 647-653.
8. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther, 1999, 84, 413-428.
9. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol, 2006, 291, C1208-C1212. (Pubitemid 44878591)
10. Echaniz-Laguna A, Mohr M, Tranchant C: Neuromuscular symptoms and elevated creatinine kinase after statin withdrawal. N Engl J Med, 2010, 362 564-565.
11. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubrov-Raz G, Pollak U et al.: Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol, 2010, 48, 407-414.
12. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apotosis of vascular smooth muscle cells in culture. Circ Res, 1998, 83, 490-500. (Pubitemid 28411050)
13. Guyton JR: Benefit versus risk in statin treatment. Am J Cardiol, 2006, 97, 95C-97C.
14. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH: Outcomes in 45 patients with statin associated myopathy. Arch Intern Med, 2005, 165, 2671-2676. (Pubitemid 41785067)
15. Harper CR, Jacobson TA: Evidence-based management of statin myopathy. Curr Atheroscler Rep, 2010, 12, 322-330.
16. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet, 2002, 360, 7-22.
17. Hippisley-Cox J, Coupland C: Individualising the risks of statins in men and women in England and Wales: population-based cohort study. Heart, 2010, 96, 939-947.
18. Jacobson TA: Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc, 2008, 83, 687-700.
19. Joy TR, Hegele R: Narrative review: statin-related myopathy. Ann Intern Med, 2009, 150, 858-868.
20. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation, 2006, 114, 2788-2797. (Pubitemid 46018281)
21. Klopstock T: Drug-induced myopathies. Curr Opin Neurol, 2008, 21, 590-595.
22. Kobayashi M, Kaido F, Kagawa T, Itagaki S, Hirano T, Iseki K: Preventive effects of bicarbonate on cerivastatin- induced apoptosis. Int J Pharm, 2007, 341, 181-188. (Pubitemid 47088121)
23. Kuncl RW: Agents and mechanisms of toxic myopathy. Curr Opin Neurol, 2009, 22, 506-515.
24. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, Sciacco M et al.: Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol, 2005, 62, 1709-1712. (Pubitemid 41626667)
25. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM et al.: Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005, 352, 1425-1435. (Pubitemid 40471450)
26. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol, 2006, 97, 52C-60C.
27. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998, 279, 1200-1205. (Pubitemid 28193431)
28. Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC: Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by imparing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J Pharmacol Exp Ther, 2007, 321, 626-634. (Pubitemid 46624499)
29. 2+] in cultured endothelial cells. Pol J Pharmacol, 2004, 56, 313-318.
30. Magee CN, Medani SA, Leavey SF, Conlon PJ, Clarkson MR: Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. Am J Kidney Dis, 2010, 56, e11-15.
31. Mammen AL, Amato AA: Statin myopathy: a review of recent progress. Curr Opin Rheumatol, 2010, 22, 644-650.
32. Marcoff L, Thompson PD: The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol, 2007, 49, 2231-2237. (Pubitemid 46856819)
33. McKenney JM, Davidson MH, Jacobson TA, Guyton JR: National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol, 2006, 97, 89C-94C.
34. Meador BM, Huey K: Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve, 2010, 42, 469-476.
35. Meda C, Plank C, Mykhaylyk O, Schmidt K, Mayer B. Effects of statins on nitric oxide/cGMP signaling in human umbilical veinendothelial cells. Pharmacol Rep, 2010, 62, 100-112.
36. Owczarek J, Jasińska M, Orszulak-Michalak D: Drug-induced myopaties. An overview of the possible mechanisms. Pharmacol Rep, 2005, 57, 23-34. (Pubitemid 40601538)
37. Pennisi G, Vacante M, Russo C, Malaguarnera M: Rhabdomyolysis induced by rosuvastatin and sildenafil. South Med J, 2010, 103, 1052-1054.
38. Pierno S, De Luca A, Tricarico D, Roselli A, Natuzzi F, Ferrannini E, Laico M, Camerino DC: Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther, 1995, 275, 1490-1496. (Pubitemid 26129941)
39. Scandinavian Simvastatin Survival Study (4S) Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
40. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R et al.: ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361, 1149-1158. (Pubitemid 36398384)
41. SEARCH Collaborative. SLCO1B1 variants and statin-induced myopathy: a Genomewide study. N Engl J Med, 2008, 359, 789-799.
42. Sirvent P, Mercier J, Lacampagne A: New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol, 2008, 8, 333-338.
43. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rabdomyolysis. N Engl J Med, 2002, 346, 539-540.
44. Stȩpień K, Tomaszewski M, Czuczwar SJ: Neuroprotective properties of statins. Pharmacol Rep, 2005, 57, 561-569.
45. Thomas JE, Lee N, Thompson PD: Statins provoking MELAS syndrome. A case report. Eur Neurol, 2007, 57, 232-235. (Pubitemid 46701482)
46. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA, 2003, 289, 1681-1690. (Pubitemid 37430274)
47. Vladutiu GD: Genetic predisposition to statin myopathy. Curr Opin Rheumatol, 2008, 20, 648-655.
48. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi N et al.: Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve, 2006, 34, 153-162. (Pubitemid 44167798)
49. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS: TheSLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol, 2009, 54, 1609-1616.
50. World Health Organization. International Drug Monitoring: The Role of the Hospital. Geneva, Switzerland: World Health Organization; 1966. Technical Report Series No. 425.
51. 10 supplementation on simvastatin-induced myalgia. Am J Cardiol, 2007, 100, 1400-1403.